ACIXF (Acarix AB) 6-Month Price Index: 0.70 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACIXF Acarix AB ACIXF
44 GF Score
Price $0.02
GF Value $0.02
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Acarix AB 6-Month Price Index?

Acarix AB ACIXF 44 6-Month Price Index is 0.70 as of Jul. 29, 2026. GuruFocus rates ACIXF with a GF Score™ of 44/100 and a GF Value™ of $0.02 (Fairly Valued). The stock has 1 warning sign investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-07-29), Acarix AB's 6-Month Price Index is 0.70.


Acarix AB  (OTCPK:ACIXF) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.


Acarix AB 6-Month Price Index Related Terms


ACIXF vs ABT, SYK, MDT: 6-Month Price Index Comparison

For the Medical Devices subindustry, Acarix AB's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ACIXF
44GF Score
Acarix AB ACIXF
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acarix AB  (OTCPK:ACIXF) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.70 mean?
Acarix AB (ACIXF) has a 6-Month Price Index of 0.70 as of Jul. 29, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Acarix AB and its competitors.
Is Acarix AB's 6-Month Price Index too high?
Acarix AB's current 6-Month Price Index is 0.70. Overall, Acarix AB has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's 6-Month Price Index compare to ABT and SYK?
Acarix AB's 6-Month Price Index of 0.70 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Medical Devices & Instruments company?
A good 6-Month Price Index depends on the Medical Devices & Instruments industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Acarix AB and its competitors. Acarix AB's current 6-Month Price Index is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Fairly Valued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 9% above its estimated fair value. The current 6-Month Price Index is 0.70. Acarix AB's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Acarix AB (ACIXF), the current 6-Month Price Index is 0.70 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acarix AB (ACIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of $0.02 is trading 9% above its estimated GF Value™ of $0.02. GuruFocus considers Acarix AB to be Fairly Valued.

Key valuation signals for ACIXF:

  • 6-Month Price Index: 0.70
  • GF Value™: $0.02 vs. price of $0.02 (9% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Acarix AB Business Description

Other Exchanges ACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score

Get the complete analysis for ACIXF

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price
$0.02
GF Value